Interferon therapy: Pharmacokinetic and pharmacological aspects

Billiau, Alfons

doi:10.1007/bf01318595

Cited by 55 publications

(9 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The discrepancy in evaluation of effectiveness of IFN between our case and previous cases ( 2 , 3,4), may be due to I) types of IFNs; 2) doses of injected IFNs; 3) route of administration: intramuscularly, intravenously, intraventricularly or intrathecally ; and 4) stage of the disease.…”

Section: Iycontrasting

confidence: 79%

Intrathecal Administration of Human Leukocyte Interferon to a Patient with Subacute Sclerosing Panencephalitis

et al. 1985

View full text Add to dashboard Cite

show abstract

Section: Iycontrasting

confidence: 79%

Intrathecal Administration of Human Leukocyte Interferon to a Patient with Subacute Sclerosing Panencephalitis

et al. 1985

View full text Add to dashboard Cite

show abstract

“…They concluded that the IV route gave superior peak levels, but both the time to peak values and the rate of clearance were the same for both routes. The removel of these groups from lymphoblastoid interferon is known to markedly alter its clearance in animals [2,3]. At this dose, detectable levels were noted at 24 h. Sherwin et al reported peak interferon values at 6 h and sustained 24-h levels in a fixed multiple-dose recombinant leukocyte interferon study [22].…”

Section: Discussionmentioning

confidence: 99%

The treatment of cancer patients with human lymphoblastoid interferon

Knost

Sherwin

Abrams

et al. 1983

Cancer Immunol Immunother

View full text Add to dashboard Cite

Highly purified human lymphoblastoid interferon (HLBI) derived from virus-stimulated Namalwa cells was administered by 6-h IV infusion or IM injection to 40 patients with a variety of disseminated malignancies refractory to standard therapy. Each patient received doses escalating from 0.1 to 50 X 10(6) U for up to 5 weeks. Extensive monitoring for clinical effect, toxicity, and pharmacokinetics has revealed higher peak serum interferon levels and somewhat more pronounced systemic toxicity for the IV than for the IM route of administration. Objective evidence of tumor regression was observed in two patients receiving HLBI IV.

show abstract

“…Since peripheral IFN ( a , p, y) do not appear to cross the blood-brain barrier (Billiau, 1981;Poindron et al, 1981), VIP-induced IFN could be a novel way by which brain cells respond to endogenous neurotransmitters. It may be speculated that IFN alp released by glial cells in response to VIP or poly (I).poly (C,,U) plays an important role in protecting the brain against viruses and in generating immune response in the CNS.…”

Section: Vip Induced 2'5'a Synthetase and Antiviralmentioning

confidence: 99%

Induction by vasoactive intestinal peptide of interferon α/β synthesis in glial cells but not in neurons

Chelbi-Alix

Brouard

Boissard

et al. 1994

Journal Cellular Physiology

View full text Add to dashboard Cite

Vasoactive intestinal peptide (VIP), a 28-amino acid peptide, plays a multifunctional neuromodulatory role in both peripheral and central nervous systems. We have recently reported that VIP induces interferon (IFN) alpha/beta synthesis in human colon adenocarcinoma cell line HT-29. It has been reported that VIP may counteract HIV-induced neuronal cell death; therefore, we postulated that the action of VIP may be mediated by a cascade regulation, involving the production of some cytokines such as IFN. Here we demonstrate that primary cultures of rat mesencephalic neurons and glial cells respond differently to VIP. Thus VIP enhanced 2'5' oligoadenylate (2'5' A) synthetase activity and inhibited vesicular stomatitis virus multiplication in glial cultures only. However, both cell cultures had functional adenylate cyclase coupled receptors for VIP. The increase in 2'5'A synthetase activity in glial cultures reached a maximum with 10(-6) M VIP and required cellular RNA and protein synthesis. Anti-IFN alpha/beta, but not anti-IFN gamma, antibodies abolished the induction of the antiviral and 2'5'A synthetase activities by VIP in rat glial-enriched cultures, suggesting that these inductions were mediated through IFN alpha/beta synthesis. Moreover, VIP or poly (i). poly (C12U) caused, in the glial cultures, the induction and secretion of an IFN of type alpha/beta with a titer value of 16 and 32 units/ml respectively. In contrast, neither of these two substances was able to induce IFN synthesis in neurons, which were, however, sensitive to IFN alpha/beta produced by VIP-treated glial cells. IFN produced by VIP in glial cells may therefore play an important role in defending the brain against viruses.

show abstract

Interferon therapy: Pharmacokinetic and pharmacological aspects

Cited by 55 publications

References 68 publications

Intrathecal Administration of Human Leukocyte Interferon to a Patient with Subacute Sclerosing Panencephalitis

Intrathecal Administration of Human Leukocyte Interferon to a Patient with Subacute Sclerosing Panencephalitis

The treatment of cancer patients with human lymphoblastoid interferon

Induction by vasoactive intestinal peptide of interferon α/β synthesis in glial cells but not in neurons

Contact Info

Product

Resources

About